Literature DB >> 16292550

Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab--monitoring of antiphospholipid and anti-GP antibodies: a case report.

R Trappe, A Loew, P Thuss-Patience, B Dörken, H Riess.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16292550     DOI： 10.1007/s00277-005-0028-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  10 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 2.  Prevalence of secondary hematologic disorders in the antiphospholipid syndrome: impact on coagulation risk.

Authors:  Sharon L Kolasinski
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 3.  Use of rituximab in the antiphospholipid syndrome.

Authors:  Deepak Kumar; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 4.  The challenge of bleeding in antiphospholipid antibody-positive patients.

Authors:  Giulia Pazzola; Stéphane Zuily; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

Review 5.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

6.  Drug treatment-induced downregulation of antiphospholipid antibodies in PAPS.

Authors:  Ingrid Boehm
Journal:  Clin Rheumatol       Date:  2009-08-20       Impact factor: 2.980

Review 7.  Perioperative management of antiphospholipid antibody-positive patients.

Authors:  Katherine H Saunders; Doruk Erkan; Michael D Lockshin
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

Review 8.  The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Authors:  D G Arkfeld
Journal:  Rheumatol Int       Date:  2007-10-24       Impact factor: 2.631

Review 9.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

Review 10.  Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?

Authors:  Ilaria Mormile; Francescopaolo Granata; Alessandra Punziano; Amato de Paulis; Francesca Wanda Rossi
Journal:  Biomedicines       Date:  2021-02-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.